Literature DB >> 22245312

Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users.

Thomas Kerr1, Brandon D L Marshall, M-J Milloy, Ruth Zhang, Silvia Guillemi, Julio S G Montaner, Evan Wood.   

Abstract

BACKGROUND: Previous studies suggest that active drug use may compromise HIV treatment among HIV-positive injection drug users (IDU). However, little is known about the differential impacts of cocaine injection, heroin injection, and combined cocaine and heroin injection on plasma HIV-1 RNA suppression.
METHODS: Data were derived from a longstanding open prospective cohort of HIV-positive IDU in Vancouver, Canada. Kaplan-Meier methods and Cox proportional hazards regression were used to examine the impacts of different drug use patterns on rates of plasma HIV-1 RNA suppression.
RESULTS: Between May 1996 and April 2008, 267 antiretroviral (ART) naïve participants were seen for a median follow-up duration of 50.6 months after initiating ART. The incidence density of HIV-1 RNA suppression was 65.2 (95%CI: 57.0-74.2) per 100 person-years. In Kaplan-Meier analyses, compared to those who abstained from injecting, individuals injecting heroin, cocaine, or combined heroin/cocaine at baseline were significantly less likely to achieve viral suppression (all p<0.01). However, none of the drug use categories remained associated with a reduced rate of viral suppression when considered as time-updated variables (all p>0.05).
CONCLUSIONS: Active injecting at the time of ART initiation was associated with lower plasma HIV-1 RNA suppression rates; however, there was no difference in suppression rates when drug use patterns were examined over time. These findings imply that adherence interventions for active injectors should optimally be applied at the time of ART initiation.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245312      PMCID: PMC3342432          DOI: 10.1016/j.drugalcdep.2011.12.019

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  35 in total

1.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

Authors:  Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization.

Authors:  Julie Bruneau; Susan B Brogly; Mark W Tyndall; François Lamothe; Eduardo L Franco
Journal:  Addiction       Date:  2004-06       Impact factor: 6.526

3.  Staging for antiretroviral therapy among HIV-infected drug users.

Authors:  Evan Wood; Robert S Hogg; Simon Bonner; Thomas Kerr; Kathy Li; Anita Palepu; Silvia Guillemi; Martin T Schechter; Julio S G Montaner
Journal:  JAMA       Date:  2004-09-08       Impact factor: 56.272

4.  Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.

Authors:  Anita Palepu; Mark Tyndall; Benita Yip; Michael V O'Shaughnessy; Robert S Hogg; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2003-04-15       Impact factor: 3.731

5.  Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.

Authors:  G M Lucas; L W Cheever; R E Chaisson; R D Moore
Journal:  J Acquir Immune Defic Syndr       Date:  2001-07-01       Impact factor: 3.731

6.  Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study.

Authors:  Andrew R Moss; Judith A Hahn; Sharon Perry; Edwin D Charlebois; David Guzman; Richard A Clark; David R Bangsberg
Journal:  Clin Infect Dis       Date:  2004-09-27       Impact factor: 9.079

7.  Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Authors:  Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg
Journal:  CMAJ       Date:  2003-09-30       Impact factor: 8.262

8.  Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants.

Authors:  N Galai; M Safaeian; D Vlahov; A Bolotin; D D Celentano
Journal:  Am J Epidemiol       Date:  2003-10-01       Impact factor: 4.897

9.  Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users.

Authors:  A Loughlin; L Metsch; L Gardner; P Anderson-Mahoney; M Barrigan; S Strathdee
Journal:  AIDS Care       Date:  2004-05

10.  Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.

Authors:  Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner
Journal:  Ann Intern Med       Date:  2003-11-18       Impact factor: 25.391

View more
  23 in total

1.  HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence.

Authors:  Hannah Fraser; Christinah Mukandavire; Natasha K Martin; Matthew Hickman; Myron S Cohen; William C Miller; Peter Vickerman
Journal:  Int J Epidemiol       Date:  2017-04-01       Impact factor: 7.196

2.  Mortality and virological failure among HIV-infected people who inject drugs on antiretroviral treatment in China: An observational cohort study.

Authors:  Yan Zhao; Mingjie Zhang; Cynthia X Shi; Jie Huang; Fujie Zhang; Keming Rou; Zunyou Wu
Journal:  Drug Alcohol Depend       Date:  2016-11-19       Impact factor: 4.492

3.  Methadone maintenance therapy and viral suppression among HIV-infected opioid users: The impacts of crack and injection cocaine use.

Authors:  M Eugenia Socías; Evan Wood; Will Small; Huiru Dong; Jean Shoveller; Thomas Kerr; Julio Montaner; M-J Milloy
Journal:  Drug Alcohol Depend       Date:  2016-09-20       Impact factor: 4.492

4.  Dispensation of antiretroviral therapy and methadone maintenance therapy at the same facility in a low-barrier setting linked to optimal adherence to HIV treatment.

Authors:  N A Mohd Salleh; N Fairbairn; S Nolan; R Barrios; J Shoveller; L Richardson; M-J Milloy
Journal:  HIV Med       Date:  2019-07-29       Impact factor: 3.180

5.  Heroin Use and HIV Disease Progression: Results from a Pilot Study of a Russian Cohort.

Authors:  E Jennifer Edelman; Debbie M Cheng; Evgeny M Krupitsky; Carly Bridden; Emily Quinn; Alexander Y Walley; Dmitry A Lioznov; Elena Blokhina; Edwin Zvartau; Jeffrey H Samet
Journal:  AIDS Behav       Date:  2015-06

6.  Acceptability of HIV Pre-exposure Prophylaxis (PREP) Among People Who Inject Drugs (PWID) in a Canadian Setting.

Authors:  Daniel J Escudero; Thomas Kerr; Evan Wood; Paul Nguyen; Mark N Lurie; Omar Sued; Brandon D L Marshall
Journal:  AIDS Behav       Date:  2015-05

7.  Prescription Opioid Injection Among HIV-Positive People Who Inject Drugs in a Canadian Setting.

Authors:  Stephanie Lake; Thomas Kerr; Jane Buxton; Silvia Guillemi; Surita Parashar; Julio Montaner; Evan Wood; M-J Milloy
Journal:  AIDS Behav       Date:  2016-12

8.  Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfected patients: results from the ANRS-CO13-HEPAVIH cohort.

Authors:  Perrine Roux; Caroline Lions; Julien Cohen; Maria Winnock; Dominique Salmon-Céron; Firouze Bani-Sadr; Philippe Sogni; Bruno Spire; François Dabis; Maria Patrizia Carrieri
Journal:  Antivir Ther       Date:  2013-10-28

9.  Increased Prevalence of Controlled Viremia and Decreased Rates of HIV Drug Resistance Among HIV-Positive People Who Use Illicit Drugs During a Community-wide Treatment-as-Prevention Initiative.

Authors:  M-J Milloy; Evan Wood; Thomas Kerr; Bob Hogg; Silvia Guillemi; P Richard Harrigan; Julio Montaner
Journal:  Clin Infect Dis       Date:  2015-11-08       Impact factor: 9.079

10.  Socioeconomic marginalization and plasma HIV-1 RNA nondetectability among individuals who use illicit drugs in a Canadian setting.

Authors:  Lindsey A Richardson; Thomas H Kerr; Sabina Dobrer; Cathy M Puskas; Silvia A Guillemi; Julio S G Montaner; Evan Wood; M-J S Milloy
Journal:  AIDS       Date:  2015-11-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.